A functional and quantitative mutational analysis of p53 mutations in yeast indicates strand biases and different roles of mutations in DMBA- and BBN-induced tumors in rats
Kazuhisa Yamamoto
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorDaichi Nakata
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorMitsuhiro Tada
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorHidefumi Tonoki
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorTakashi Nishida
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorAtsuko Hirai
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorYi Ba
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorTetsuya Aoyama
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorJun-ichi Hamada
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorKeiji Furuuchi
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorHiroshi Harada
Department of Pathology, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorKei Hirai
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorNobuhisa Shibahara
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorYoji Katsuoka
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorCorresponding Author
Tetsuya Moriuchi
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, N-17, W-5, Kita-ku, Sapporo 060-8638, Japan. Fax: 0(81) 11-706-7870.Search for more papers by this authorKazuhisa Yamamoto
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorDaichi Nakata
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorMitsuhiro Tada
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorHidefumi Tonoki
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorTakashi Nishida
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorAtsuko Hirai
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorYi Ba
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorTetsuya Aoyama
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorJun-ichi Hamada
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorKeiji Furuuchi
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorHiroshi Harada
Department of Pathology, Hokkaido University School of Medicine, Sapporo, Japan
Search for more papers by this authorKei Hirai
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorNobuhisa Shibahara
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorYoji Katsuoka
Department of Urology, Osaka Medical University, Takatsuki, Japan
Search for more papers by this authorCorresponding Author
Tetsuya Moriuchi
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, N-17, W-5, Kita-ku, Sapporo 060-8638, Japan. Fax: 0(81) 11-706-7870.Search for more papers by this authorAbstract
In order to analyze the mutational events and to understand the biological significance of the p53 gene in chemical carcinogenesis, we applied a new yeast-based p53 functional assay to ovarian tumors induced by 7, 12-dimethylbenz[a]anthracene (DMBA), as well as to transitional cell carcinomas of the urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats. The assay demonstrated that 15 of 19 DMBA induced tumors harbored clonal p53 mutations, which is consistent with the expectations of the “clonal expansion” hypothesis. The majority of the mutations were purine (AG) to pyrimidine (CT) transversions (12/19) on the non-transcribed (sense) strand (NTS), which is likely to be due to depurination created by DMBA adduct formation on the NTS. In contrast, we found no purine to pyrimidine transversion on the NTS. After cessation of BBN treatment, BBN-induced multifocal lesions in the bladder contained heterogeneous p53 mutations at an early stage. In the later stage, however, clonal p53 mutations were identified in 4 out of 7 bladders analyzed, conforming with the concept of “field cancerization”. The observed base substitutions were G→A (1/6) or C →T transitions (2/6), and mutations at T (3/6) on the NTS in clonal mutations, together with non-clonal mutations, showing a preference of C→T to G→A (17 vs. 0). Thus, preferential repair was found in the transcribed strand of the p53 gene, whether modified by DMBA or by BBN carcinogens. Very similar mutation patterns were observed between clonal and non-clonal mutations in the DMBA- and BBN-induced tumors, indicating that the rat yeast p53 functional assay can be a potential tool for the characterization of in vivo mutation patterns of p53, when modified by chemical carcinogens. Int. J. Cancer 83:700-705, 1999. © 1999 Wiley-Liss, Inc.
REFERENCES
- Asamoto, M., Mann, A.M., and Cohen, S.M.. p53 mutation is infrequent and might not give a growth advantage in rat bladder carcinogenesis in vivo. Carcinogenesis, 15, 455–458 (1994). Medline
- Bhanot, O.S., Grevatt, P.C., Donahue, J.M., Gabrielides, C.N., and Solomon, J.J., In vitro DNA replication implicates O2-ethyldeoxythymidine in transversion mutagenesis by ethylating agents. Nucleic Acid Res., 20, 587–594 (1992). Medline
- Bronstein, S.M., Skopek, T.R., and Swenberg, J.A., Efficient repair of O6-ethylguanine, but not O4-ethylthymine or O2- ethylthymine, is dependent upon O6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. Cancer Res., 52, 2008–2011 (1992). Medline
- Cabral Neto, J.B., Cabral, R.E., Margot, A., Le Page, F., Sarasin, A., and Gentil, A., Coding properties of a unique apurinic/apyrimidinic site replicated in mammalian cells. J. Mol. Biol., 240, 416–420 (1994). Medline
- Chakravarti, D., Pelling, J.C., Cavalieri, E.L., and Rogan, E.G., Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc. nat. Acad. Sci (Wash.), 92, 10422–10426 (1995).
- Chang, K.W., Lin, S.C., Koos, S., Pather, K., and Solt, D., p53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas. Carcinogenesis, 17, 595–600 (1996). Medline
- Cohen, S.M., Urinary bladder carcinogenesis. Toxicol. Pathol., 26, 121–127 (1998). Medline
- Dogliotti, E., Mutational spectra: from model systems to cancer-related genes. Carcinogenesis, 17, 2113–2118 (1996). Medline
- Dumaz, N., Drougard, C., Sarasin, A., and Daya-Grosjean, L., Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA repair deficient xeroderma pigmentosum patients. Proc. nat. Acad. Sci. (Wash.), 90, 10529–10533 (1993).
- Flaman, J.-M., and 13 OTHERS, A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. nat. Acad. Sci. (Wash.), 92, 3963–3967 (1995).
- Hainaut, P., Hernandez, T., Robinson, A., Rodriguez Tome, P., Flores, T., Hollstein, M., Harris, C.C., and Montesano, R., IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26, 205–213 (1998). Medline
- Heflich, R.H., Mittelstaedt, R.A., Manjanatha, M.G., Lyn-Cook, L.E., and Aidoo, A., DNA sequence analysis of hprt mutations in lymphocytes from Sprague-Dawley rats treated with 7, 12-dimethylbanz[a]anthracene. Environ. mol. Mutagenesis, 28, 2–12 (1996).
- International Union Against Cancer TNM classification of malignant tumors., ( 4th ed.) p. 133–135, Springer, New York (1987).
- Japanese Urological Association and the japanese pathological society, General rules for clinical and pathological studies on bladder cancer, ( 3 ed.), Kanehara Shuppan, Tokyo (1992).
- Kanjilal, S., Pierceall, W.E., Cummings, K.K., Kripke, M.L., and Ananthaswamy, H.N., High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity. Cancer Res., 53, 2961–2964 (1993). Medline
-
Kato, T.,
Yakushiji, M.,
Tsunawaki, A., and
Ide, K.,
Studies on experimental ovarian tumors; Ovarian tumors developed in rats receiving chemical carcinogen 9, 10-dimethy-1, 2, benzanthracene.
Kurume med. J.,
21, 11–19
(1974).
10.2739/kurumemedj.21.11 Google Scholar
-
Kito, K.,
Kihana, T.,
Sugita, A.,
Murao, S.,
Akehi, S.,
Sato, M.,
Tachibana, M.,
Kimura, S., and
Ueda, N.,
Incidence of p53 and Ha-ras gene mutations in chemically induced rat mammary carcinomas.
Mol. Carcinogenesis,
17, 78–83
(1996).
Medline
10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- Levine, A.J., p53, the cellular gatekeeper for growth and division. Cell, 88, 323–331 (1997). Medline
- Manjanatha, M.G., Chen, J.B., Shaddock, J.G. Jr., Harris, A.J., Shelton, S.D., and Casciano, D.A., Molecular analysis of lacI mutations in Rat2 cells exposed to 7,12- dimethylbenz[a]anthracene: evidence for DNA sequence and DNA strand biases for mutation. Mutation Res., 372, 53–64 (1996). Medline
- Masui, T., Don, I., Takada, N., Ogawa, K., Shirai, T., and Fukushima, S., p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 15, 2379–2381 (1994). Medline
- Masui, T., Dong, Y., Yamamoto, S., Takada, N., Nakanishi, H., Inada, K., Fukushima, S., and Tatematsu, M., p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Lett., 105, 105–112 (1996). Medline
- Moll, U.M., and Schramm, L.M., p53—an acrobat in tumorigenesis. Crit. Rev. Oral Biol. Med., 9, 23–37 (1998). Medline
- Mozzherin, D.J., Shibutani, S., Tan, C.K., Downey, K.M., and Fisher, P.A., Proliferating cell nuclear antigen promotes DNA synthesis past template lesions by mammalian DNA polymerase d. Proc. nat. Acad. Sci. (Wash.), 94, 6126–6131 (1997).
- Ren, Z.-P., Hedrum, A., PontÉn, F., Nister, M., Ahmadian, A., Lundeberg, J., Uhlén, M., and PontÉn, J., Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene, 12, 765–773 (1996). Medline
- Shirai, T., Shibata, M., Takahashi, S., Tagawa, Y., Imaida, K., and Hirose, M., Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-pretreated. Carcinogenesis, 16, 501–505 (1995). Medline
- Soussi, T., Caron de Fromentel, C., Breugnot, C., and May, E., Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. Nucleic Acids Res., 16, 11384 (1988). Medline
- Soussi, T., Caron de Fromentel, C., and May, P., Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5, 945–952 (1990). Medline
- Stotz, A., and Linder, P., The ADE2 gene from Saccharomyces cerevisiae: sequence and new vectors. Gene, 95, 91–98 (1990). Medline
- Strauss, B.S., The ‘A rule’ of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? Bioessays, 13, 79–84 (1991). Medline
- Waridel, F., Estreicher, A., Bron, L., Flaman, J.M., Fontolliet, C., Monnier, P., Frebourg, T., and Iggo, R., Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene, 14, 163–169 (1997). Medline
- Yamamoto, S., Chen, T., Murai, T., Mori, S., Morimura, K., Oohara, T., Makino, S., Tatematsu, M., Wanibuchi, H., and Fukushima, S., Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 18, 1877–1882 (1997). Medline
- Yamamoto, S., Masui, T., Murai, T., Mori, S., Oohara, T., Makino, S., Fukushima, S., and Tatematsu, M., Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 16, 2363–2368 (1995). Medline